United Therapeutics Corp
NASDAQ:UTHR
United Therapeutics Corp
Cash Interest Paid
United Therapeutics Corp
Cash Interest Paid Peer Comparison
Competitive Cash Interest Paid Analysis
Latest Figures & CAGR of Competitors
Company | Cash Interest Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
United Therapeutics Corp
NASDAQ:UTHR
|
Cash Interest Paid
$55.5m
|
CAGR 3-Years
48%
|
CAGR 5-Years
28%
|
CAGR 10-Years
26%
|
|
Abbvie Inc
NYSE:ABBV
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash Interest Paid
$42m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
5%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is United Therapeutics Corp's Cash Interest Paid?
Cash Interest Paid
55.5m
USD
Based on the financial report for Mar 31, 2024, United Therapeutics Corp's Cash Interest Paid amounts to 55.5m USD.
What is United Therapeutics Corp's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 10Y
26%
Over the last year, the Cash Interest Paid growth was 46%. The average annual Cash Interest Paid growth rates for United Therapeutics Corp have been 48% over the past three years , 28% over the past five years , and 26% over the past ten years .